Original InvestigationEfficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
The study was funded by AstraZeneca Pharmaceuticals LP. AstraZeneca was responsible for study conduct, data collection, and analysis. The study was designed by AstraZeneca in conjunction with Drs. Stein and Kastelein. The initial drafts of the manuscript were done by Dr. Stein, Prof. Raal, and Dr. Kastelein, who had full access to the study data. All authors reviewed and had input to the final draft. The academic authors vouch for the validity of the data in the final manuscript. Dr. Stein has received consultant and expert witness fees from AstraZeneca regarding statins. Dr. Gaudet has served as a consultant or advisor for AstraZeneca, Regeneron, Sanofi, Amgen, Aegerion, Chiesi, Gemphire, Novartis, Ionis, Cymabay, Uniqure, and Catabasis; and has received research funding from AstraZeneca. Dr. Sokal has received consultant and expert witness fees from AstraZeneca regarding statins and from Promethera Biosciences, Abbvie, Alexion, and Shire not related to statins; and is chief science officer of Promethera Biosciences. Dr. Mohamed has received consultant and advisor fees from AstraZeneca. Drs. Raichlen, Sundén, and Carlsson are employees of AstraZeneca. Prof. Raal has received research grants and consultant or lecture fees from AstraZeneca, Merck, Pfizer, Regeneron, Sanofi, and Amgen. Dr. Kastelein has received grant support from AstraZeneca, Pfizer, Roche, Novartis, Merck, Merck/Schering-Plough, Ionis, Genzyme, and Sanofi; lecture fees from AstraZeneca, GlaxoSmithKline, Pfizer, Novartis, Merck/Schering-Plough, Roche, Ionis, and Boehringer Ingelheim; and consulting fees from AstraZeneca, Abbott, Pfizer, Ionis, Genzyme, Roche, Novartis, Merck, Merck/Schering-Plough, and Sanofi. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.